Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

To evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL.

Trial Details

NCT ID
NCT07244406
Phase
PHASE2
Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • S1904 CD19 CAR-T
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Sign the informed consent and be willing and able to comply with the visit, treatment regimen, laboratory examination and other requirements of the…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →